Literature DB >> 11961234

Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.

Satoshi Saito1, Satoshi Ota, Hideyuki Seshimo, Yuichiro Yamazaki, Setsuo Nomura, Toshihiro Ito, Jun Miki, Masao Ota, Hirofumi Fukushima, Hiroo Maeda.   

Abstract

BACKGROUND: HLA-C antigens have been thought to be of little significance in determining the efficacy of platelet transfusions. However, six alloimmunized patients were encountered who were refractory to platelet transfusions because of anti-HLA-Cw3, -Cw3, -Cw7, or -Cw8. STUDY DESIGN AND METHODS: Between 1995 and the present, 88 patients with hematologic malignancies became refractory to random-donor platelet transfusions due to HLA antibodies. HLA-A- and HLA-B-compatible platelet transfusions were successful in boosting platelet levels with 82 of the patients. This study concerns the remaining six HLA-immunized patients who were refractory to HLA-A- and HLA-B-compatible platelet transfusions. The response to the platelet transfusions was assessed by calculating both 1- and 24-hour posttransfusion CCIs for each transfusion.
RESULTS: The average CCI(1 hour) and CCI(24 hours) in all patients were 20.0 and 12.8 for HLA-A-, HLA-B-, and HLA-C-compatible transfusions and were 1.4 and 1.2 for HLA-A- and HLA-B-compatible but HLA-C-incompatible transfusions, respectively (p < 0.001).
CONCLUSION: These findings clearly indicate that matching of the HLA-C antigens is also required in some alloimmunized patients to obtain the effectiveness of platelet transfusions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961234     DOI: 10.1046/j.1537-2995.2002.00051.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

Review 1.  Toward in Vitro Production of Platelet from Induced Pluripotent Stem Cells.

Authors:  Elaheh Izady; Zohreh Saltanatpour; Li-Ping Liu; Akram Alizadeh; Amir Ali Hamidieh
Journal:  Stem Cell Rev Rep       Date:  2022-04-09       Impact factor: 6.692

2.  Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.

Authors:  Ying Liu; Yufan Zhang; Dawei Chen; Yongshui Fu
Journal:  Front Med (Lausanne)       Date:  2022-05-06

3.  Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion.

Authors:  Jeremy Ryan A Peña; Susan L Saidman; Timothy C Girouard; Erin Meister; Walter H Dzik; Robert S Makar
Journal:  Am J Hematol       Date:  2014-06-19       Impact factor: 10.047

4.  Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions.

Authors:  Osama S Salama; Doaa A Aladl; Doaa M El Ghannam; Wesam E Elderiny
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 5.  Generation and manipulation of human iPSC-derived platelets.

Authors:  Naoshi Sugimoto; Koji Eto
Journal:  Cell Mol Life Sci       Date:  2021-01-13       Impact factor: 9.261

Review 6.  Generation of HLA Universal Megakaryocytes and Platelets by Genetic Engineering.

Authors:  Constanca Figueiredo; Rainer Blasczyk
Journal:  Front Immunol       Date:  2021-10-27       Impact factor: 7.561

7.  Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.

Authors:  Bijender Kumar; Vahid Afshar-Kharghan; Mayela Mendt; Robert Sackstein; Mark R Tanner; Uday Popat; Jeremy Ramdial; May Daher; Juan Jimenez; Rafet Basar; Luciana Melo Garcia; Mayra Shanley; Mecit Kaplan; Xinhai Wan; Vandana Nandivada; Francia Reyes Silva; Vernikka Woods; April Gilbert; Ricardo Gonzalez-Delgado; Sunil Acharya; Paul Lin; Hind Rafei; Pinaki Prosad Banerjee; Elizabeth J Shpall
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

8.  Simultaneous genotyping for human platelet antigen systems and HLA-A and HLA-B loci by targeted next-generation sequencing.

Authors:  Jielin Wang; Xuan You; Yanmin He; Xiaozhen Hong; Ji He; Sudan Tao; Faming Zhu
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.